• Users Online: 385
  • Print this page
  • Email this page
Year : 2020  |  Volume : 4  |  Issue : 5  |  Page : 25-32

Mini-review on recent update on coronavirus disease 2019: Clinical outcome and largest pharmaceutical companies

1 Department of Microbiology & Immunology, RAK Medical and Health Sciences University, Ras Al Khaimah, UAE
2 Department of Clinical Pharmacy & Pharmacology, RAK College of Pharmaceutical Sciences, RAK Medical and Health Sciences University, Ras Al Khaimah, UAE

Correspondence Address:
Dr. Pooja Shivappa
Rak Medical and Health Sciences University, Ras Al Khaimah 11172
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/bbrj.bbrj_67_20

Rights and Permissions

The current worldwide outbreak of the novel coronavirus disease 2019 (COVID-19); the pathogen called SARS-CoV-2; previously 2019-n CoV), which originated from Wuhan in China and has now spread worldwide. This current review includes information regarding treatment and, clinical outcomes of COVID-19 patients with diabetes, liver injury, rheumatic diseases, respiratory issues, kidney problems, and breast malignant growth. The various international companies supporting the findings in the treatment/vaccine for COVID-19. There are currently no specific antiviral drugs, however, several antiviral drugs and repurposed drugs are under serious scrutiny. We encourage all readers to continue to assess clinical data as it emerges and shares their experience within our community in a well-controlled and, adequately powered fashion.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded155    
    Comments [Add]    

Recommend this journal